Disease Topics

Disease Topics

48 Disease areas packed with insight

Disease Topics

Knowledge Centres

Diagnosis, patient management, treatment strategies & decision support

Drug Database

Drug Database

Summary information on thousands of prescription drugs available in 9 languages

News

News

News written for doctors around pharmacological development

Treatment Guidelines

Clinical Guidelines

Professional association and governmental guidance on treatment

Disease Topics

Clinical Trials

Medical research & drug development - current and past landmark studies

Medical Journals

Medical Journals

Journal articles, titles and extracts from respected publishers

Disease Topics

Medical Apps

All the latest free and paid-for Apps selected for doctors

Welcome to epgonline.org - the website for healthcare professionals

What's new? The Bedwetting Knowledge Centre

Bedwetting, or nocturnal enuresis is defined as intermittent incontinence while sleeping. Applicable to children ≥ 5 years old, wetting episodes of any type that occur in discrete amounts are indicative to nocturnal enuresis.1,2

Due to variations in comorbidity, treatment response and pathogenesis, nocturnal enuresis can be divided into two subgroups – monosymptomatic nocturnal enuresis (MNE) and non-monosymptomatic nocturnal enuresis (NMNE).1,3 Absence of lower urinary tract symptoms or a history of bladder dysfunction is characteristic of MNE, while NMNE is defined as nocturnal enuresis accompanied by daytime urinary symptoms.

Nocturnal enuresis can have a profound impact on the child and their family, lowering a child’s self image, causing behavioural problems and affecting school performance. However, successful treatment improves the mental health of the child and brings practical relief to the family.

Latest News

FDA Advisory Committee rejects MoxDuo for Moderate to Severe Pain- QRxPharma

24-Apr-2014

QRxPharma announced that the FDA ...

NICE rejects Kadcyla for HER-2 positive Breast Cancer- Roche

24-Apr-2014

The The National Institute for ...

FDA approves Somatom Force CT Imaging system-Siemens

24-Apr-2014

The FDA has cleared the Somatom Force ...

Phase III trials success for tofacitinib in Plaque Psoriasis- Pfizer

23-Apr-2014

Pfizer Inc. announced top-line ...

ABT 450/r, ABT 267, ABT 333 combination submitted to FDA for Hepatitis C-AbbVie

23-Apr-2014

AbbVie has submitted a New Drug ...

FDA approves Cyramza for Gastric Cancer-Eli Lilly

23-Apr-2014

The FDA has approved Cyramza ...

Phase III trial shows Zonegran for Epilepsy well tolerated in young patients-Eisai

23-Apr-2014

Zonegran (zonisamide), from Eisai, is ...

Recent Updates

Drugs

Clinical Guidelines

Food allergy in children and young people: Diagnosis and assessment of food allergy in children and young people in primary care and community settings

Waldenström’s macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

BCSH guideline for the use of anti-D immunoglobulin for the prevention of haemolytic disease of the fetus and newborn

Best practice guidance for the diagnosis and management of cystic fibrosis-associated liver disease

Medical Journals

Daily profiles of energy and nutrient intakes: are eating profiles changing over time?

Health-related quality of life in chronic myeloid leukemia

Poor Sensitivity of a Modified Alvarado Score in Adults With Suspected Appendicitis

Standardized outpatient management of Klebsiella pneumoniae liver abscesses

epgonline.org Social